ADMA Biologics, Inc. (ADMA) Stock Analysis

Why this analysis is different

• A sector-relative MoonshotScore — five pillars (business quality, financial safety, valuation, growth durability, momentum) re-ranked nightly against the full universe of US-listed common stocks.
• An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
• Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.

ADMA Biologics, Inc. (ADMA) Healthcare & Pipeline Overview

ADMA Biologics, Inc. develops and markets specialty plasma-derived biologics, focusing on immune deficiencies and infectious diseases. Its key products, BIVIGAM and ASCENIV, target primary humoral immunodeficiency, supported by plasma collection facilities and sales through diverse channels in a competitive biopharmaceutical landscape.

What Is the Investment Thesis for ADMA?

With a profit margin of 32.4% and a gross margin of 61.3%, the company demonstrates strong profitability. Key value drivers include the continued growth of BIVIGAM and ASCENIV sales, driven by increasing awareness and diagnosis of primary immunodeficiency. The development and potential commercialization of its pipeline products, particularly those targeting S. pneumonia infection, represent significant growth catalysts. However, investors should be aware of the company's negative free cash flow of $-0.03B and the competitive landscape. The company's beta of 0.59 suggests lower volatility compared to the market. Successful execution of its pipeline development and strategic expansion of its plasma collection network are crucial for sustained growth and shareholder value creation.

Based on FMP financials and quantitative analysis

ADMA Key Highlights

Market capitalization of $2.18B reflects investor confidence in ADMA's growth potential.

• P/E ratio of 11.07 indicates a potentially undervalued stock relative to its earnings.
• Profit margin of 32.4% demonstrates strong profitability in the biopharmaceutical sector.
• Gross margin of 61.3% highlights efficient cost management in plasma-derived biologics manufacturing.
• Beta of 0.59 suggests lower volatility compared to the overall market, appealing to risk-averse investors.

Who Are ADMA's Competitors?

ADMA is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance

What Are ADMA's Key Strengths?

Specialized expertise in plasma-derived biologics.

• Established product portfolio with BIVIGAM and ASCENIV.
• Proprietary manufacturing processes.
• Network of plasma collection facilities.

What Are ADMA's Weaknesses?

Negative free cash flow.

• Reliance on plasma supply.
• Limited geographic presence.
• Competition from larger biopharmaceutical companies.

What Could Drive ADMA Stock Higher?

Clinical trial results for pipeline products targeting S. pneumonia infection.

• Expansion of plasma collection facilities to increase supply.
• Increased awareness and diagnosis of primary immunodeficiency (PI) driving demand for BIVIGAM and ASCENIV.

What Are the Key Risks for ADMA?

Inconsistent delivery — missed Wall Street EPS estimates in 4 of the last 8 reported quarters.

• Regulatory changes and compliance requirements impacting manufacturing and distribution.
• Competition from biosimilars eroding market share.
• Fluctuations in plasma supply and pricing affecting profitability.
• Product liability and safety concerns leading to recalls or lawsuits.
• Negative free cash flow requiring additional financing.

What Are the Growth Opportunities for ADMA?

• Expansion of Plasma Collection Facilities: ADMA can drive growth by strategically expanding its network of plasma collection facilities. This ensures a consistent and cost-effective supply of high-quality plasma, a critical raw material for its products. The global plasma fractionation market is projected to reach $46.8 billion by 2028, indicating substantial growth potential. Investing in new facilities and optimizing existing ones will enhance ADMA's production capacity and reduce reliance on external suppliers, improving profitability and supply chain resilience.
• Pipeline Development and Commercialization: ADMA's pipeline of plasma-derived therapeutics, particularly those targeting S. pneumonia infection, represents a significant growth opportunity. Successful development and commercialization of these products would expand ADMA's product portfolio and address unmet medical needs. The market for pneumonia vaccines and therapies is substantial, with the global pneumonia market expected to reach $5.3 billion by 2027. Positive clinical trial results and regulatory approvals would be key catalysts for this growth driver.
• Geographic Expansion: ADMA currently focuses on the United States and international markets. Expanding its geographic presence into new regions, particularly emerging markets with growing healthcare expenditures, could drive significant revenue growth. The global biopharmaceutical market is expected to reach $510 billion by 2026, with emerging markets contributing a significant portion of this growth. Strategic partnerships and targeted marketing efforts will be crucial for successful geographic expansion.
• Strategic Acquisitions and Partnerships: ADMA can pursue strategic acquisitions and partnerships to expand its product portfolio, access new technologies, and enhance its market position. Collaborating with other biotechnology companies or acquiring complementary assets can accelerate innovation and drive revenue growth. The biopharmaceutical industry is characterized by frequent mergers and acquisitions, with deal values reaching billions of dollars annually. Identifying synergistic opportunities and executing successful integrations will be key to realizing the benefits of this growth strategy.
• Increased Awareness and Diagnosis of Primary Immunodeficiency: Driving increased awareness and diagnosis of primary immunodeficiency (PI) can lead to greater demand for ADMA's BIVIGAM and ASCENIV products. Many individuals with PI remain undiagnosed, representing a significant untapped market. Educational campaigns targeted at healthcare professionals and patients can increase diagnosis rates and expand the patient base for ADMA's therapies. The global market for immunodeficiency treatments is expected to grow, driven by increasing awareness and improved diagnostic tools.

What Are ADMA's Competitive Advantages?

• Specialized expertise in plasma-derived biologics.
• Proprietary manufacturing processes for IVIG products.
• Network of plasma collection facilities ensuring supply.
• Established relationships with distributors and specialty pharmacies.

What Does ADMA Do?

ADMA Biologics, Inc., founded in 2004 and headquartered in Ramsey, New Jersey, is a biopharmaceutical company dedicated to developing, manufacturing, and marketing specialty plasma-derived biologics. The company focuses on treatments for immune deficiencies and infectious diseases, addressing critical unmet needs in these therapeutic areas. ADMA's product portfolio includes BIVIGAM, an intravenous immune globulin (IVIG) indicated for primary humoral immunodeficiency (PI), and ASCENIV, another IVIG product also targeting PI. Additionally, the company offers Nabi-HB for acute exposure to Hepatitis B. Beyond its existing products, ADMA Biologics is actively developing a pipeline of plasma-derived therapeutics, including treatments and preventatives for S. pneumonia infection. A key component of ADMA's operations is its network of source plasma collection facilities, which ensures a consistent supply of high-quality plasma for manufacturing its products. The company distributes its products through a variety of channels, including independent distributors, sales agents, specialty pharmacies, and other alternate site providers, ensuring broad access for patients in need. ADMA's commitment to innovation and quality positions it as a significant player in the plasma-derived biologics market.

What Products and Services Does ADMA Offer?

• Develops specialty plasma-derived biologics.
• Manufactures plasma-derived therapies for immune deficiencies.
• Markets biologics for the treatment of infectious diseases.
• Offers BIVIGAM for primary humoral immunodeficiency (PI).
• Provides ASCENIV, an IVIG product for PI treatment.
• Supplies Nabi-HB for Hepatitis B exposure.
• Operates source plasma collection facilities.
• Develops therapeutics for S. pneumonia infection.

How Does ADMA Make Money?

• Develops and manufactures plasma-derived biologics.
• Sells products through independent distributors and specialty pharmacies.
• Operates plasma collection facilities to ensure supply.
• Focuses on treatments for immune deficiencies and infectious diseases.

What Industry Does ADMA Operate In?

ADMA Biologics operates within the biotechnology industry, specifically focusing on plasma-derived therapies. The market for these therapies is driven by the increasing prevalence of immune deficiencies and infectious diseases, coupled with advancements in plasma fractionation and purification technologies. The competitive landscape includes major players like LGND and smaller, specialized companies. The industry is subject to stringent regulatory oversight by the FDA, requiring significant investments in research, development, and manufacturing. Overall, the biotechnology industry is experiencing growth, fueled by innovation and unmet medical needs, with plasma-derived therapies playing a crucial role.

Who Are ADMA's Key Customers?

• Patients with primary humoral immunodeficiency (PI).
• Individuals exposed to Hepatitis B.
• Hospitals and clinics treating immune deficiencies.
• Specialty pharmacies dispensing plasma-derived therapies.

Over the past six months, ADMA Biologics, Inc. insiders filed 13 SEC Form 4 transactions — 6 sales and 7 purchases. On net that is roughly 208K shares acquired (about $922K) — insiders putting money in tends to read as conviction.

Quarterly Financial Performance: ADMA Biologics, Inc.

Revenue for ADMA Biologics, Inc. came in at $124.4M during Jun 2026, a 8.6% improvement versus the preceding quarter. The company recorded net income of $37.8M, with diluted EPS of $0.16. Quarter-over-quarter revenue has been mixed, typical for a mid-cap company operating in Healthcare. Across the four most recent quarters, ADMA averaged $0.18 in diluted EPS.

ADMA Valuation & Market Position

With a $2.18B market cap, ADMA Biologics, Inc. sits in the mid-cap segment of the market. Analyst price targets span from $17.00 to $21.00, with a consensus of $18.67. At the current price of $9.42, that implies approximately 98% upside potential. Relative to its peer group, ADMA's quantitative score of 92/100 is above the peer average of 82/100.

Return on equity for ADMA Biologics, Inc. stands at 39.0%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is 24.9%, showing how much profit it generates from its asset base. ADMA trades at a trailing price-to-earnings ratio of 11.07, below the Healthcare sector average of ~21.60x. Its free cash flow yield is 6.0%, a gauge of the cash the business throws off relative to its market value. A current ratio of 6.95 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is 9.0%, the inverse of the P/E and a quick read on earnings relative to price.

ADMA Biologics, Inc.'s Piotroski F-Score is 6/9, a 9-point checklist of profitability, leverage and efficiency — a middling fundamental profile. Its Altman Z-Score of 7.19 places it in the safe zone, indicating low near-term bankruptcy risk.

ADMA Biologics, Inc. has missed Wall Street's EPS estimate in 4 of its last 8 reported quarters — a mixed record worth weighing. Reported results have landed about 1.0% above estimates on average.

Wall Street analysts project ADMA Biologics, Inc. revenue of about $535.3M for fiscal 2026, with EPS near $0.80.

Company Profile

ADMA Biologics, Inc. operates in the Biotechnology industry within the Healthcare sector. It is headquartered in Ramsey, US. The company is led by CEO Adam S. Grossman. ADMA has traded publicly since 2013.

ADMA Financials

ADMA Latest News

ADMA Analyst Consensus

ADMA MoonshotScore

Latest ADMA Biologics, Inc. Analysis

What Investors Ask About ADMA Biologics, Inc. (ADMA) — Healthcare

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources